Your AI-Trained Oncology Knowledge Connection!
Leslie M. Randall, MD; Thomas C. Krivak, MD; Rebecca C. Arend, MD, MPH; Tara Berman, MD, MS; and Gottfried E. Konecny, MD, discuss how molecular testing and biomarker-driven treatment strategies are revolutionizing gynecologic oncology across ovarian, cervical, and endometrial cancers.
Rebecca Shatsky, MD; Rita Nanda, MD; Kelly McCann, MD, PhD; Nusayba Bagegni, MD; and Alexis LeVee, MD,discuss how recent advances in hormone receptor–positive breast cancer treatment, including oral SERDs such as elacestrant, PI3K pathway inhibitors, and antibody-drug conjugates such as T-DXd, are being integrated into clinical practice based on biomarkers such as ESR1 mutations and HER2-low expression while addressing key sequencing decisions and resistance mechanisms in the evolving therapeutic landscape.
John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS, MD, and Katrina S. Pedersen, MD discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for MSI-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.
Luciano Costa, MD, PhD; Jing Christine Ye, MD, MSc; Samer Al Hadidi, MD, MS; and Binod Dhakal, MD, discuss how the multiple myeloma treatment landscape has evolved with quadruplet therapies becoming standard for newly diagnosed patients regardless of transplant eligibility, CAR T and bispecific antibodies showing promise for earlier use in relapsed/refractory disease, and emerging dual-targeting therapies potentially offering cure for some patients rather than just prolonged treatment.
Daneng Li, MD; Lowell B. Anthony, MD, FACP; Christopher Lieu, MD; and Chandrikha Chandrasekharan, MBBS, discuss how the treatment landscape for neuroendocrine tumors has evolved significantly over the past few decades with the introduction of multiple therapeutic options including somatostatin analogs, targeted therapies like everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT), and the recent approval of cabozantinib, which provides new sequencing opportunities and fills treatment gaps for heavily pretreated patients while emphasizing the importance of individualized patient care and shared decision-making in this complex disease.
David C. Fisher, MD; Lauren C. Pinter-Brown, MD; Barbara Pro, MD; and Sima Rozati, MD, PhD, discuss how to optimize cutaneous T-cell lymphoma treatment through multidisciplinary care; compartment-specific therapy selection; management of treatment-related complications, such as mogamulizumab-associated rash; and strategic use of combination therapies while addressing critical unmet needs including biomarker development and improved quality of life measures.
Experts discuss key indications for alloHSCT and emerging GVHD prophylaxis strategies, as well as explore a novel investigational allogeneic T-cell immunotherapy, Orca-T, and its clinical impact in the field of transplantation.
Dr Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Dr Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific adviser role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences. Dr Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Dr Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Dr Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.
Vamsidhar Velcheti, MD, MBA, FASCO, FACP, FCCP; Jessica Donington, MD, MSCR; Jaspal Singh, MD; and Joshua Sabari, MD, discuss how optimizing early-stage non–small cell lung cancer (NSCLC) management through a multidisciplinary approach enhances treatment outcomes and improves patient care.
Andre Goy, MD; Jamie Koprivnikar, MD, and Harsh Parmar, MD, discuss how recent advancements in CAR T-cell therapies, bispecific antibodies, and targeted treatments are transforming the management of hematologic malignancies, with particular focus on real-world comparative analyses of different approaches in multiple myeloma, lymphoma, and leukemia.
Experts discuss the evolving treatment landscape in advanced renal cell carcinoma (RCC), focusing on optimal treatment selection and sequencing strategies, with insights from recent clinical trial updates presented at ASCO GU 2025 and their potential impact on clinical practice.
Shubham Pant, MD, MBBS; Haley Ellis, MD; Amit Mahipal, MD; and Darshil Shah, MD, MPH, examine the evolving landscape of biliary tract cancer management, covering critical aspects from initial prognosis communication through biomarker testing strategies, first-line immunotherapy combinations, and the emergence of HER2-targeted therapies, while highlighting recent clinical trial data and ongoing challenges in optimizing patient outcomes.
Neil M. Iyengar, MD; Sara A. Hurvitz, MD, FACP; Laura Huppert, MD; Anne P. O’Dea, MD; and Melinda L. Telli, MD, discuss how recent trials, particularly DESTINY-Breast04/06, TROPiCS-02, and TROPION-Breast01, have revolutionized the HER2-low/ultralow breast cancer treatment landscape, demonstrating efficacy of novel antibody-drug conjugates such as trastuzumab deruxtecan while emphasizing the importance of careful patient selection, standardized testing, and strategic sequencing of these emerging therapies.
Cesar Rodriguez, MD; Yvonne A. Efebera, MD; Natalia Neparidze, MD; and Omar Nadeem, MD, examine how treatment approaches for transplant-ineligible/deferred newly diagnosed multiple myeloma are evolving through clinical trials like CEPHEUS, IMROZ, and BENEFIT, which demonstrate improved outcomes with anti–CD38-based quadruplet regimens while considering factors such as MRD negativity, administration methods, and patient selection criteria for optimizing therapeutic strategies.
William J. Gradishar, MD, provides insights on the evolving treatment landscape of breast cancer management, highlighting updates to NCCN guidelines, the growing role of CDK4/6 inhibitors, and anticipated research findings at ASCO 2024.
Join leading global experts as they discuss the latest research and treatment advancements in CLL from the ASH 2024 Annual Meeting. Moderated by Dr. John Seymour, this peer exchange features in-depth insights from top clinicians across Europe.
Leading experts discuss the evolving treatment landscape in diffuse large B-cell lymphoma (DLBCL), focusing on front-line therapies, second-line immunotherapies, and strategies for managing relapsed/refractory cases."
Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is offering transformative insights, with JTCC highlighting the latest tumor-targeted therapies and biomarker-driven treatments that are shaping the future of personalized cancer care and improving patient outcomes.
This 12-part OncLive® Peer Exchange series, Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights, features expert-led discussions moderated by Dr. Matthew Lunning and focuses on the latest clinical data and evolving treatment strategies in relapsed/refractory follicular lymphoma. With insights from ASH 2024, including the inMIND and EPCORE NHL-2 trials, the panel explores second- and third-line therapies, bispecifics, CAR T-cell therapies, and practical guidance for optimizing patient care.
Panelists discuss how recent advances in chronic GVHD treatment, including emerging therapies like ruxolitinib, ibrutinib, and belumosudil, are reshaping management strategies by emphasizing early intervention, treatment sequencing, and the potential of combination therapies to improve patient outcomes.
Panelists discuss how recent advancements in CAR T-cell therapies, including the FDA approval of obe-cel and updates from the ZUMA-3 and FELIX trials, are reshaping the treatment landscape for relapsed/refractory ALL, with a focus on patient selection, bridging therapies, toxicity management, and health care resource utilization.
Panelists discuss how recent advancements in the treatment of polycythemia vera and myelofibrosis, including the role of JAK inhibitors, cytoreductive therapy, and emerging therapies, are shaping current clinical practice and guiding personalized treatment strategies.
Panelists discuss how recent advancements in targeted therapies, particularly the FDA-approved menin inhibitor revumenib, are reshaping the treatment landscape for relapsed/refractory acute monocytic leukemia (R/R AML), offering new options for high-risk patients while emphasizing the importance of genetic testing and minimal residual disease monitoring in guiding therapy.
Matthew S. Davids, MD, MMSc; Alvaro Alencar, MD; Marc S. Hoffmann, MD; Brad S. Kahl, MD, and Nicole Lamanna, MD,engage in a comprehensive discussion of frontline CLL treatment strategies, examining factors influencing the choice between fixed-duration venetoclax-based therapy and continuous BTK inhibitors, analyzing long-term SEQUOIA trial data, evaluating real-world outcomes and adverse events with covalent BTK inhibitors, and assessing emerging combination approaches including zanubrutinib plus venetoclax.
Panelists discuss how recent advancements in treatment strategies for ALK-positive and BRAF-positive V600E NSCLC, including efficacy updates and the management of brain metastases, can enhance personalized care and optimize patient outcomes.
Panelists discuss how recent advancements in the treatment of newly diagnosed multiple myeloma (MM) and early relapse, particularly the role of chimeric antigen receptor T-cell therapy, are reshaping therapeutic strategies and improving patient outcomes.
This series delves into recent advancements in the treatment of advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), focusing on clinical trial findings from FLAURA2, ADAURA, TROPION-Lung01, and HERTHENA-Lung01 and their implications for optimizing patient management and survival outcomes.
Panelists discuss how recent advancements in frontline and second-line therapies for unrespectable hepatocellular carcinoma (uHCC) are reshaping treatment strategies and improving patient outcomes.
In this OncLive Peer Exchange series, a panel of experts discusses the latest advancements in the management of gynecological cancers, highlighting updates from ESMO 2024, including treatment paradigms for advanced ovarian, cervical, and endometrial cancers, biomarker testing strategies, and emerging therapies such as antibody-drug conjugates.
Panelists discuss how recent clinical trials and innovative therapies are reshaping the treatment landscape for small cell lung cancer, emphasizing the importance of personalized approaches and multidisciplinary strategies to improve patient outcomes.
Elias Jabbour, MD; Evandro D. Bezerra, MD; Lori Muffly, MD; Jae H. Park, MD, and Gregory W. Roloff, MD,review the role of CAR T-cell therapy\ for relapsed/refractory acute lymphoblastic leukemia, address adverse event management and supportive care, and highlight significant updates presented at the American Society of Clinical Oncology and European Hematology Association 2024 conferences.
